Search results for "PROGRESSION-FREE SURVIVAL"

showing 10 items of 147 documents

Colorectal cancer with microsatellite instability: Right-sided location and signet ring cell histology are associated with nodal metastases, and extr…

2021

Colorectal cancer (CRC) with microsatellite instability (MSI) accounts for 15-18 % of all CRCs and represents the category with the best prognosis. This study aimed at determining any possible clinical/pathological features associated with a higher risk of nodal metastasization in MSI-CRC, and at defining any possible prognostic moderators in this setting. All surgically resected CRCs of the last 20 years (mono-institutional series) with a PCR-based diagnosis of MSI, with and without nodal metastasis, have been retrieved for histological review, which was performed following WHO guidelines. Furthermore, the most important prognostic moderators have been investigated with a survival analysis…

AdultMale0301 basic medicineOncologycongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPrognostic variableColonColorectal cancerDisease-Free SurvivalMetastasisPathology and Forensic MedicineMetastasis03 medical and health sciences0302 clinical medicineInternal medicinedMMRmedicinerectumHumansStage (cooking)neoplasmsMSISurvival analysisAgedColon; ENE; Extracapsular; MSI; Metastasis; dMMR; rectumExtranodal ExtensionExtracapsularSignet ring cellbusiness.industryColon; dMMR; ENE; Extracapsular; Metastasis; MSI; rectumMicrosatellite instabilityCell BiologyMiddle AgedPrognosismedicine.diseaseProgression-Free Survivaldigestive system diseases030104 developmental biology030220 oncology & carcinogenesisENEFemaleMicrosatellite InstabilityColorectal NeoplasmsNODALbusinessCarcinoma Signet Ring CellPathology - Research and Practice
researchProduct

Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial

2018

Background:Gastric cancer is common malignancy and exhibits a poor prognosis. At the time of diagnosis, the majority of patients present with metastatic disease which precludes curative treatment. Non-invasive biomarkers which discriminate early from advanced stages or predict the response to treatment are urgently required. This study explored the cytokeratin-18 fragment M30 and full-length cytokeratin-18 M65 in predicting treatment response and survival in a randomized, placebo-controlled trial of advanced gastric cancer.Methods:Patients enrolled in the SUN-CASE study received sunitinib or placebo as an adjunct to standard therapy with leucovorin (Ca-folinate), 5-fluorouracil, and irinote…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyIndolesmedicine.medical_treatmentLeucovorinAntineoplastic AgentsPlaceboDisease-Free SurvivalMetastasislaw.inventionPlacebos03 medical and health sciences0302 clinical medicineRandomized controlled trialStomach NeoplasmslawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorSunitinibHumansMedicinePyrrolesProgression-free survivalRC254-282AgedAged 80 and overChemotherapyKeratin-18business.industrySunitinibCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMiddle Agedmedicine.diseasePeptide FragmentsIrinotecan030104 developmental biology030220 oncology & carcinogenesisCamptothecinFemaleFluorouracilbusinessmedicine.drugTumor Biology
researchProduct

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer

2016

This analysis confirms that administering neoadjuvant chemotherapy (NACT) before chemoradiotherapy (CRT) could be a potential option for high-risk, locally advanced rectal cancer. In this setting, MRI tumour regression grade is an independent prognostic factor and, when assessed after NACT, may predict the probability and magnitude of incremental benefit from sequential CRT.EXPERT and EXPERT-C were phase II clinical trials of neoadjuvant chemotherapy (NACT) followed by chemoradiotherapy (CRT) in high-risk, locally advanced rectal cancer (LARC). We pooled individual patient data from these trials. The primary objective was overall survival (OS) in the intention-to-treat (ITT) population. Pro…

AdultMale0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentPopulationPhases of clinical researchKaplan-Meier EstimateDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProgression-free survivalStage (cooking)educationNeoadjuvant therapyAgedAged 80 and overeducation.field_of_studyIntention-to-treat analysisRectal Neoplasmsbusiness.industrySurrogate endpointChemoradiotherapyHematologyMiddle AgedMagnetic Resonance ImagingNeoadjuvant TherapyTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalbusinessChemoradiotherapy
researchProduct

Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hod…

2015

Aim To investigate the respective influence of software tool and total metabolic tumor volume (TMTV0) calculation method on prognostic stratification of baseline 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography ([18F]FDG-PET) in newly diagnosed Hodgkin lymphoma (HL). Methods 59 patients with newly diagnosed HL were retrospectively included. [18F]FDG-PET was performed before any treatment. Four sets of TMTV0 were calculated with Beth Israel (BI) software: based on an absolute threshold selecting voxel with standardized uptake value (SUV) >2.5 (TMTV02.5), applying a per-lesion threshold of 41% of the SUVmax (TMTV041) and using a per-patient adapted threshold based on SUVmax of the…

AdultMaleAdolescentAbsolute thresholdlcsh:MedicineGlucose-6-PhosphateStandardized uptake valueDisease-Free SurvivalPredictive Value of TestsImage Processing Computer-AssistedmedicineHumansProgression-free survivallcsh:ScienceSurvival rateAgedMultidisciplinarymedicine.diagnostic_testReceiver operating characteristicbusiness.industrylcsh:RMiddle AgedHodgkin DiseaseRadiographySurvival RatePositron emission tomographyPositron-Emission TomographyPredictive value of testsHodgkin lymphomalcsh:QFemaleNuclear medicinebusinessSoftwareResearch ArticleFollow-Up StudiesPLOS ONE
researchProduct

Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors.

2010

More than 90% of all Ewing's Sarcoma Family of Tumors (ESFT) exhibit specific chromosomal rearrangements between the EWS gene on chromosome 22 and various members of the ETS gene family of transcription factors. The gene fusion type and other secondary genetic alterations, mainly involving cell cycle regulators, have been shown to be of prognostic relevance in ESFT. However, no conclusive results have been reported. We analyzed the clinicopathological significance of relevant cell cycle regulators in genetically confirmed ESFT. A total of 324 cases were analyzed for the immunohistochemical expression of p53, p21(Waf1/Cip1) , p27(Kip1) and Ki67 and the chromosomal alterations of the p53 and …

AdultMaleCancer ResearchPathologymedicine.medical_specialtyAdolescentChromosomes Human Pair 22Sarcoma EwingBiologyFusion geneCohort StudiesYoung AdultGene mappingmedicineBiomarkers TumorHumansProgression-free survivalChildIn Situ Hybridization FluorescenceAgedAged 80 and overCell CycleCancerEwing's sarcomaInfantCell cycleMiddle Agedmedicine.diseaseGenes p53ImmunohistochemistryOncologyChild PreschoolCancer researchFemaleSarcomaChromosome DeletionRNA-Binding Protein EWSChromosome 22International journal of cancer
researchProduct

Spinal ependymoma in adults: a multicenter investigation of surgical outcome and progression-free survival

2018

OBJECTIVESpinal ependymomas are rare glial neoplasms. Because their incidence is low, only a few larger studies have investigated this condition. There are no clear data concerning prognosis and therapy. The aim of the study was to describe the natural history, perioperative clinical course, and local tumor control of adult patients with spinal ependymomas who were surgically treated under modern treatment standards.METHODSThe authors performed a multicenter retrospective study. They identified 158 adult patients with spinal ependymomas who had received surgical treatment between January 2006 and June 2013. The authors analyzed the clinical and histological aspects of these cases to identif…

AdultMaleEpendymomaMicrosurgerymedicine.medical_specialtyAdolescentSpinal intradural tumormedicine.medical_treatmentYoung Adult03 medical and health sciences0302 clinical medicineRecurrenceNeoplasmsBiomarkers TumormedicineHumansSpinal Cord NeoplasmsProgression-free survivalGrading (tumors)AgedRetrospective StudiesAged 80 and overSpinal cordbusiness.industryIncidence (epidemiology)Retrospective cohort studyGeneral MedicinePerioperativeMiddle AgedPrognosismedicine.diseaseProgression-Free Survivalddc:616.8SurgeryRadiation therapyKi-67 AntigenLocalOncologyEpendymomaTumor progression030220 oncology & carcinogenesisFemaleRadiotherapy AdjuvantNeoplasm Recurrence Localbusiness030217 neurology & neurosurgeryFollow-Up StudiesJournal of Neurosurgery: Spine
researchProduct

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

2013

Abstract Background A combination of bortezomib (1.3 mg/m2), melphalan (5 mg/m2), and dexamethasone (40 mg) (BMD), with all three drugs given as a contemporary intravenous administration, was retrospectively evaluated. Patients and methods Fifty previously treated (median 2 previous lines) patients with myeloma (33 relapsed and 17 refractory) were assessed. The first 19 patients were treated with a twice-a-week (days 1, 4, 8, 11, ‘base’ schedule) administration while, in the remaining 31 patients, the three drugs were administered once a week (days 1, 8, 15, 22, ‘weekly’ schedule). Results Side-effects were predictable and manageable, with prominent haematological toxicity, and a better tox…

AdultMaleMelphalanmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSalvage therapyGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleBortezomibRefractoryRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalMelphalanMultiple myelomaDexamethasoneAgedRetrospective StudiesAged 80 and overBortezomibbusiness.industryHematologyMiddle Agedmedicine.diseaseBoronic AcidsRegimenTreatment OutcomeOncologyPyrazinesInjections IntravenousFemaleMultiple MyelomabusinessFollow-Up Studiesmedicine.drug
researchProduct

Final results from a randomized phase 3 study of FOLFIRI \pm$ panitumumab for second-line treatment of metastatic colorectal cancer

2013

Abstract: Background: The study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased overall survival (OS) with panitumumab-FOLFIRI versus FOLFIRI alone for second-line wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Updated long-term data from a prespecified descriptive analysis are reported. Patients and methods: Patients receiving one prior mCRC treatment were randomly assigned (1:1) to panitumumab (6.0 mg/kg)-FOLFIRI versus FOLFIRI every 2 weeks. Co-primary end points (PFS and OS) were prospectively analyzed by tumor KRAS status. Results: One thousand one hundred and eighty-six patient…

AdultMaleOncologymedicine.medical_specialtyBevacizumabColorectal cancerLeucovorinPhases of clinical researchKaplan-Meier Estimatemedicine.disease_causeSkin DiseasesDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPanitumumabProgression-free survivalAgedAged 80 and overbusiness.industryPanitumumabLiver NeoplasmsHazard ratioAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseTreatment OutcomeOncologyQuality of LifeFOLFIRICamptothecinFemaleFluorouracilKRASHuman medicineColorectal Neoplasmsbusinessmedicine.drugAnnals of oncology
researchProduct

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODI…

2021

Abstract Immune checkpoint inhibitors have failed in treating metastatic colorectal cancer (mCRC) patients except those with dMMR/MSI tumors. However, until very recently we had only non-comparative promising data in this population with anti-programmed cell death 1/ programmed cell death ligand 1 (PD1/PD-L1) antibodies alone or combined with anti- cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibodies. This comparative phase II trial (NCT 03186326), conducted in more than 100 centers in France, will include dMMR/MSI mCRC patients with progression after a first-line treatment with chemotherapy ± targeted therapies, to evaluate efficacy and safety of the anti-PDL1 Avelumab versus a s…

AdultMaleOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPopulationECOG Performance StatusAntibodies Monoclonal HumanizedAvelumab03 medical and health sciencesAntineoplastic Agents ImmunologicalClinical Trials Phase II as Topic0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMulticenter Studies as TopiceducationRandomized Controlled Trials as TopicChemotherapyeducation.field_of_studyHepatologybusiness.industryGastroenterologyMicrosatellite instabilityImmunotherapymedicine.diseaseProgression-Free SurvivalRegimen030220 oncology & carcinogenesisFemaleMicrosatellite Instability030211 gastroenterology & hepatologyFranceColorectal Neoplasmsbusinessmedicine.drugDigestive and Liver Disease
researchProduct

Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer

2018

Aim The aim of this retrospective multicentre study was to evaluate the clinical and prognostic effect of fluorine-18-fluorodeoxyglucose (18F-FDG)-PET/computed tomography (CT) in the restaging process of pancreatic cancer (PC). Materials and methods Data from patients treated for primary PC, who underwent18F-FDG-PET/CT for suspicious of disease progression, were collected. Accuracy was assessed employing conventional diagnostic procedures, multidisciplinary team case notes, further18F-FDG-PET/CT scans and/or follow-up. Receiver operating characteristic curve and likelihood ratio (LR+/-) analyses were used for completion of accuracy definition. Progression-free survival (PFS) and overall sur…

AdultMalePrognosioverall survival18F-FDG-PET/CTpancreatic cancer030218 nuclear medicine & medical imaging03 medical and health sciencesdisease progression0302 clinical medicineRetrospective StudieFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyPancreatic cancerrestagingHumansMedicineRadiology Nuclear Medicine and imagingProgression-free survivalRetrospective StudiesAgedNeoplasm StagingReceiver operating characteristicbusiness.industryProportional hazards modelHazard ratioPancreatic NeoplasmArea under the curveRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseConfidence intervalPancreatic Neoplasms030220 oncology & carcinogenesisFemalebusinessNuclear medicineprogression-free survivalHumanNuclear Medicine Communications
researchProduct